Crescita Therapeutics Inc.
CRRTF
$0.3901
-$0.0013-0.33%
| Weiss Ratings | CRRTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | CRRTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | CRRTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -5.90 | |||
| Price History | CRRTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | -0.33% | |||
| 60-Day Total Return | -13.12% | |||
| 90-Day Total Return | -13.12% | |||
| Year to Date Total Return | -13.12% | |||
| 1-Year Total Return | 21.72% | |||
| 2-Year Total Return | -23.51% | |||
| 3-Year Total Return | -20.39% | |||
| 5-Year Total Return | -41.78% | |||
| 52-Week High % Change | -14.58% | |||
| 52-Week Low % Change | 1,757.62% | |||
| Price | CRRTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.46 | |||
| 52-Week Low Price | $0.02 | |||
| 52-Week Low Price (Date) | Aug 15, 2024 | |||
| 52-Week High Price (Date) | Oct 01, 2024 | |||
| Valuation | CRRTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 7.33M | |||
| Enterprise Value | 2.11M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.11 | |||
| Earnings Per Share Growth | 335.92% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.59 | |||
| Price/Book (Q) | 0.63 | |||
| Enterprise Value/Revenue (TTM) | 0.18 | |||
| Price | $0.39 | |||
| Enterprise Value/EBITDA (TTM) | -1.74 | |||
| Enterprise Value/EBIT | -1.01 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | CRRTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 19.27M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CRRTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 800 361 0352 | |||
| Address | 2805 Place Louis-R Renaud Laval, QC H7V 0A3 | |||
| Website | www.crescitatherapeutics.com | |||
| Country | Canada | |||
| Year Founded | 2016 | |||
| Profitability | CRRTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -17.55% | |||
| Profit Margin | -15.70% | |||
| Management Effectiveness | CRRTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -7.90% | |||
| Return on Equity | -- | |||
| Income Statement | CRRTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 12.80M | |||
| Total Revenue (TTM) | 12.80M | |||
| Revenue Per Share | $0.66 | |||
| Gross Profit (TTM) | 7.11M | |||
| EBITDA (TTM) | -1.31M | |||
| EBIT (TTM) | -2.25M | |||
| Net Income (TTM) | -2.01M | |||
| Net Income Avl. to Common (TTM) | -2.01M | |||
| Total Revenue Growth (Q YOY) | 16.54% | |||
| Earnings Growth (Q YOY) | 20.53% | |||
| EPS Diluted (TTM) | -0.11 | |||
| EPS Diluted Growth (Q YOY) | 15.99% | |||
| Balance Sheet | CRRTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 6.25M | |||
| Cash Per Share (Q) | $0.32 | |||
| Total Current Assets (Q) | 12.05M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 11.89M | |||
| Current Ratio (Q) | 2.698 | |||
| Book Value Per Share (Q) | $0.62 | |||
| Total Assets (Q) | 16.79M | |||
| Total Current Liabilities (Q) | 4.47M | |||
| Total Debt (Q) | 685.40K | |||
| Total Liabilities (Q) | 4.90M | |||
| Total Common Equity (Q) | 11.89M | |||
| Cash Flow | CRRTF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -1.30M | |||
| Cash from Financing (TTM) | -646.50K | |||
| Net Change in Cash (TTM) | -1.16M | |||
| Levered Free Cash Flow (TTM) | -405.30K | |||
| Cash from Operations (TTM) | 799.20K | |||
